Headquartered in Wayne, PA Fiscal year ends December NYSE: TFX teleflex.com
Teleflex Incorporated is a global provider of medical technologies offering a diverse portfolio of solutions in the therapy areas of anesthesia, emergency medicine, interventional cardiology and radiology, surgical, vascular access, and urology. The company operates through three product categories: Vascular (including vascular access, hemostatic products, central access, right heart catheters, intraosseous devices, complex catheters, and emergency medicine products including the newly FDA-approved EZPLAZ Freeze Dried Plasma), Interventional (including the acquired Biotronik Vascular Intervention business and the Freesolve drug-eluting resorbable magnesium scaffold in clinical development), and Surgical (including ligation clips, instruments, and skin stapling). Teleflex is currently undergoing a significant portfolio transformation through Strategic Divestitures of its OEM, Acute Care, and Interventional Urology businesses to sharpen focus on its core medical device operations, while simultaneously integrating the Biotronik Vascular Intervention acquisition. The company's brand portfolio includes Arrow, Barrigel, Deknatel, LMA, Pilling, QuikClot, Rüsch, UroLift, and Weck. Updated
Pre-Market Stock Futures: Futures are trading lower as we enter the final trading days of the third quarter, after a wild week in which interest rates soared and oil prices bounced back…
Pre-Market Stock Futures: Futures are trading lower as we prepare to end another up-and-down week, and, as we mentioned before, it all depends on the status of the war with Iran and…
Teleflex Incorporated is a global provider of medical technologies offering a diverse portfolio of solutions in the therapy areas of anesthesia, emergency medicine, interventional cardiology and radiology, surgical, vascular access, and urology.
24/7 Wall St.'s 12-month price target for TFX is $190.88, rated Buy. The Wall Street consensus target is $154.00. TFX price prediction →
